Therapeutic Potential of Oligo-Fucoidan in Mitigating Peritoneal Dialysis-Associated Fibrosis
2024

Oligo-Fucoidan's Role in Preventing Peritoneal Dialysis Fibrosis

Sample size: 5 publication 10 minutes Evidence: moderate

Author Information

Author(s): Chen Yu-Wei, Wu Mei-Yi, Huang Nai-Jen, Wu Mai-Szu, Hsu Yung-Ho, Liao Chia-Te, Chen Cheng-Hsien, Pliego-Cortés Hugo, Bourgougnon Nathalie

Primary Institution: Taipei Medical University

Hypothesis

Can oligo-fucoidan mitigate peritoneal dialysis-associated fibrosis through its antioxidative and anti-inflammatory properties?

Conclusion

Oligo-fucoidan effectively prevents peritoneal thickening and fibrosis in a mouse model of peritoneal dialysis.

Supporting Evidence

  • Oligo-fucoidan prevented high-glucose-induced apoptosis in human mesothelial cells.
  • High-glucose dialysate caused significant peritoneal thickening in the mouse model.
  • Oligo-fucoidan reduced the expression of pro-inflammatory cytokines in the serum of PD mice.
  • Immunohistochemical staining showed less fibrosis in oligo-fucoidan treated groups.
  • Oligo-fucoidan restored catalase expression in high-glucose treated cells.
  • High glucose increased oxidative stress and inflammation in mesothelial cells.

Takeaway

Oligo-fucoidan, a substance from brown seaweed, helps protect the body from damage caused by a type of kidney treatment called peritoneal dialysis.

Methodology

The study used human mesothelial cells and a mouse model to investigate the effects of oligo-fucoidan on peritoneal fibrosis.

Limitations

The study did not account for the systemic effects of renal diseases on peritoneal fibrosis.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/md22120529

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication